

Remarks

The foregoing amendments to the specification are made to more clearly indicate the subject matter of the present claims in the title and the abstract, as well as to update the status of prior applications. No new matter is added by this amendment to the specification, and its entry is respectfully requested.

Upon entry of the foregoing amendment Claim 28 will be pending. Claim 28 is amended to specify the particular IL-174 agonist and particular infectious disease that were recited in canceled Claims 29-30 and Claim 31, respectively. No new matter is added by this amendment to the claims, and its entry is respectfully requested.

Rejection of Claims Under 35 U.S.C. §112, first paragraph

Claims 28-29 and 31-32 were rejected as allegedly indefinite for failing to recite any specific structure for an IL-174 agonist or an IL-174 protein. Applicants respectfully request that this rejection should be withdrawn in view of the foregoing amendment.


Rejection of Claims Under 35 U.S.C. §112, first paragraph

The Office Action rejected Claims 28-32 because the specification allegedly did not enable or adequately describe treating any infectious disease other than a Helminth infection using any IL-174 agonist other than an IL-174 protein of SEQ ID NO:2. This rejection should be withdrawn in view of the foregoing amendment to the claims.

Serial Number: 10/705,183
DX01088KB
Reply Dated May 25, 2007 to
Office Action Mailed 11/29/2006

For the foregoing reasons, Applicants believe that the application and claims are in condition for allowance. If the undersigned can be of any assistance to the Examiner in resolving any new issues, please contact the undersigned at the number set forth below.

Respectfully submitted,



Melodie W. Henderson
Reg. No. 37,848

Schering-Plough Corporation
Patent Department
Mail Stop K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530

Phone: (908) 298-7482
Fax: (908) 298-5388